3SBio acquires China rights to Lilly's Humulin

Eli Lilly and Co. (NYSE:LLY) granted 3SBio Inc. (HKSE:1530) exclusive rights to distribute and promote its diabetes drug Humulin in China, beginning July 1.

Lilly's China unit will be responsible for manufacturing the drug, while 3SBio will be responsible for its marketing. Humulin, a recombinant biosynthetic insulin, has been approved in China since 1997. Lilly declined to disclose financial terms. 3SBio did not respond to inquiries...